Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | EGFR | P00533 | 6/20 | 0.55 |
| ▸ | ERBB3 | P21860 | 3/20 | 0.55 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.46 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.46 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.46 |
| ▸ | KMO | O15229 | 1/20 | 0.46 |
| ▸ | CDK4 | P11802 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 2/20 | 0.44 |
| ▸ | BCR | P11274 | 1/20 | 0.44 |
| ▸ | TEK | Q02763 | 1/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.44 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3225993 | 0.89 | MEN1 (0.57) | MEN1KMT2ANPC1RAB9AEGFR | |
| SCHEMBL691107 | 0.83 | EGFR (0.63) | MEN1KMT2ANPC1RAB9AEGFR | |
| SCHEMBL3220007 | 0.82 | S1PR1 (0.52) | MEN1KMT2ANPC1RAB9AEGFR | |
| SCHEMBL14447573 | 0.78 | NPC1 (0.55) | NPC1RAB9ASMN1; SMN2KDRTNNI3K | |
| SCHEMBL3141056 | 0.77 | CCNT1 (0.45) | MEN1KMT2ANPC1RAB9AEGFR | |
| SCHEMBL16158635 | 0.77 | EGFR (0.58) | MEN1KMT2ANPC1RAB9AEGFR | |
| SCHEMBL30046349 | 0.76 | SCN9A (0.76) | MEN1KMT2ANPC1RAB9AEGFR | |
| SCHEMBL1938761 | 0.76 | KMO (0.73) | MEN1KMT2ANPC1RAB9AEGFR | |
| SCHEMBL3231476 | 0.76 | MAPT (0.61) | MEN1KMT2ANPC1RAB9AEGFR | |
| SCHEMBL691637 | 0.76 | EGFR (0.60) | MEN1KMT2ANPC1RAB9AEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | VHL, BRCA1, TERT | MEN1 301/4885KMT2A 1604/4885NPC1 1432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.